36 results on '"Underwood, Patrick"'
Search Results
2. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma
3. Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head
4. Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
5. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors
6. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
7. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer.
8. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma
9. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients
10. Additional file 4 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
11. Additional file 6 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
12. Additional file 3 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
13. Additional file 1 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
14. Additional file 2 of Surgical resident experience with common bile duct exploration and assessment of performance and autonomy with formative feedback
15. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
16. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
17. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
18. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery
19. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
20. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
21. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
22. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
23. Abstract 955: Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy
24. Abstract 1172: Disparities in pancreatic ductal adenocarcinoma - the significance of Hispanic ethnicity, by subgroup analysis, and treatment facility on clinical outcomes
25. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
26. Tu2018 LONG-TERM OUTCOMES AFTER MINIMALLY INVASIVE IVOR LEWIS ESOPHAGECTOMY FOR CANCER
27. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer
28. Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
29. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia
30. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery.
31. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors
32. A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies
33. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
34. Matter of Words
35. Grievances and the Genesis of Rebellion:Mutiny in the Royal Navy, 1740-1820
36. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X L -Specific Degrader DT2216.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.